Bioactive concentrate from small sea fish: evaluation of the efficacy and safety of the drug on the basis of the analysis of 37 clinical trials
Injectable Alflutop® (the bioactive concentrate from small sea fish (BCSSF)) belongs to the pharmacological group of symptomatic slow-acting drugs for osteoarthritis. This drug has been widely used in our country for 25 years. During this time, 37 of its clinical trials (n=3676) have been conducted...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2020-11-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1077 |
| _version_ | 1797876713058729984 |
|---|---|
| author | A. E. Karateev |
| author_facet | A. E. Karateev |
| author_sort | A. E. Karateev |
| collection | DOAJ |
| description | Injectable Alflutop® (the bioactive concentrate from small sea fish (BCSSF)) belongs to the pharmacological group of symptomatic slow-acting drugs for osteoarthritis. This drug has been widely used in our country for 25 years. During this time, 37 of its clinical trials (n=3676) have been conducted in Russia and post-Soviet countries, mainly in patients with knee osteoarthritis (OA) and nonspecific back pain. These are mainly open-label trials, a major portion of which has been performed at the good methodological level, by using active control and up-to-date methods to assess treatment results. Two works are double-blind placebo-controlled trials (DBPCTs) conducted in compliance with the modern requirements of evidence-based medicine – this is an evaluation of the efficacy of BCSSF in knee OA and vertebrogenic lumbar ischialgia. All the trials have shown a good therapeutic potential of BCSSF: on the average, after the cycle use of the agent, there is a 40–60% decrease in pain intensity as compared to the baseline level. A two-year DBPCT of the efficacy of BCSSF in knee OA has also confirmed that the concentrate has a structure-modifying effect. At the same time, all the trials have demonstrated that BCSSF is well tolerated and very rarely causes adverse reactions that require discontinuation of treatment. |
| first_indexed | 2024-04-10T02:05:53Z |
| format | Article |
| id | doaj.art-fc4e7057482749b2a38b5e8000b1bf0b |
| institution | Directory Open Access Journal |
| issn | 1996-7012 2310-158X |
| language | Russian |
| last_indexed | 2024-04-10T02:05:53Z |
| publishDate | 2020-11-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj.art-fc4e7057482749b2a38b5e8000b1bf0b2023-03-13T08:39:28ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2020-11-0114411112410.14412/1996-7012-2020-4-111-1242305Bioactive concentrate from small sea fish: evaluation of the efficacy and safety of the drug on the basis of the analysis of 37 clinical trialsA. E. Karateev0ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»Injectable Alflutop® (the bioactive concentrate from small sea fish (BCSSF)) belongs to the pharmacological group of symptomatic slow-acting drugs for osteoarthritis. This drug has been widely used in our country for 25 years. During this time, 37 of its clinical trials (n=3676) have been conducted in Russia and post-Soviet countries, mainly in patients with knee osteoarthritis (OA) and nonspecific back pain. These are mainly open-label trials, a major portion of which has been performed at the good methodological level, by using active control and up-to-date methods to assess treatment results. Two works are double-blind placebo-controlled trials (DBPCTs) conducted in compliance with the modern requirements of evidence-based medicine – this is an evaluation of the efficacy of BCSSF in knee OA and vertebrogenic lumbar ischialgia. All the trials have shown a good therapeutic potential of BCSSF: on the average, after the cycle use of the agent, there is a 40–60% decrease in pain intensity as compared to the baseline level. A two-year DBPCT of the efficacy of BCSSF in knee OA has also confirmed that the concentrate has a structure-modifying effect. At the same time, all the trials have demonstrated that BCSSF is well tolerated and very rarely causes adverse reactions that require discontinuation of treatment.https://mrj.ima-press.net/mrj/article/view/1077биоактивный концентрат мелкой морской рыбыостеоартритнеспецифическая боль в спинетендинитбурситтрохантеритэпикондилитэффективностьбезопасность |
| spellingShingle | A. E. Karateev Bioactive concentrate from small sea fish: evaluation of the efficacy and safety of the drug on the basis of the analysis of 37 clinical trials Современная ревматология биоактивный концентрат мелкой морской рыбы остеоартрит неспецифическая боль в спине тендинит бурсит трохантерит эпикондилит эффективность безопасность |
| title | Bioactive concentrate from small sea fish: evaluation of the efficacy and safety of the drug on the basis of the analysis of 37 clinical trials |
| title_full | Bioactive concentrate from small sea fish: evaluation of the efficacy and safety of the drug on the basis of the analysis of 37 clinical trials |
| title_fullStr | Bioactive concentrate from small sea fish: evaluation of the efficacy and safety of the drug on the basis of the analysis of 37 clinical trials |
| title_full_unstemmed | Bioactive concentrate from small sea fish: evaluation of the efficacy and safety of the drug on the basis of the analysis of 37 clinical trials |
| title_short | Bioactive concentrate from small sea fish: evaluation of the efficacy and safety of the drug on the basis of the analysis of 37 clinical trials |
| title_sort | bioactive concentrate from small sea fish evaluation of the efficacy and safety of the drug on the basis of the analysis of 37 clinical trials |
| topic | биоактивный концентрат мелкой морской рыбы остеоартрит неспецифическая боль в спине тендинит бурсит трохантерит эпикондилит эффективность безопасность |
| url | https://mrj.ima-press.net/mrj/article/view/1077 |
| work_keys_str_mv | AT aekarateev bioactiveconcentratefromsmallseafishevaluationoftheefficacyandsafetyofthedrugonthebasisoftheanalysisof37clinicaltrials |